Myrtle Potter, CEO, Sumitovant Biopharma Sumitovant received two FDA NDA approvals in the past week and in its first year of operation Myrtle Potter, CEO, Sumitovant Biopharma Sumitovant received two ...

Treatment with vibegron reduced the average number of micturition episodes per day and the average number of daily urgency episodes compared with placebo. The Food and Drug Administration (FDA) has ...

SMPA reinforces commitment to the urology community with findings from studies across overactive bladder and advanced ...

The approval was based on data from the pivotal phase 3 EMPOWUR study. The Food and Drug Administration (FDA) has approved Gemtesa ® (vibegron; Urovant Sciences) for the treatment of overactive ...

New analyses of data from the Phase 3 EMPOWUR Extension Study of GEMTESA® (vibegron) 75 mg will be presented during Sunday morning’s podium session by: Jeffrey Frankel, M.D., who will report on an ...

Medicare should cover drugs for treating overactive bladder (OAB), such as Gemtesa. But whether this particular medication is covered varies depending on your specific plan. Gemtesa (vibegron) is a ...

Data from the dedicated, stand-alone, ambulatory blood pressure trial will be the focus of a virtual podium presentation Efficacy in patients with 'dry' overactive bladder, based on a post-hoc ...

Medicare drug plans should cover drugs to treat overactive bladder (OAB), which can include Gemtesa. However, whether or not this specific drug is covered depends on a person’s plan. Gemtesa is a ...

The Company's lead product, GEMTESA (vibegron), is an oral, once-daily (75 mg) small molecule beta-3 agonist for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge ...

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)-- Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ...

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences, Inc., a wholly-owned subsidiary of Sumitovant Biopharma Ltd., updates its news release originally issued August 18, 2021, to ...